Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Prognostic Impact of Subclinical FLT3 -ITD Microclones in Patients with Acute Myeloid Leukemia

Paul Olson, Razif Gabdoulline, Rabia Shahswar, Arnold Kloos, Letizia Venturini, Isabell Arnhardt, Henri C. Hupe, Victoria Panagiota, Michael Stadler, Matthias Eder, Gernot Beutel, Elke Dammann, Piroska Poll, Anke Bergmann, Nataliya DiDonato, Florian H. Heidel, Felicitas R. Thol, Michael Heuser

Blood (2024) 144 (Supplement 1): 847.

https://doi.org/10.1182/blood-2024-207703

Published: 2024

Journal Articles

The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3 -ITD Mutations

Blood (2024) 144 (Supplement 1): 844.

https://doi.org/10.1182/blood-2024-202362

Published: 2024

Journal Articles

Reliable Assessment of Iron Deficiency in Patients with Myeloproliferative Neoplasms through Fluorescence Spectroscopy-Based Measurement of Zinc Protoporphyrin (ZPP)

Kirsi Manz, Myriam Kobrosly, Carl C Crodel, Haifa Kathrin Al-Ali, Susanne Isfort, Gernot Beutel, Victoria Panagiota, Felicitas R. Thol, Stefanie Jilg, Thomas Stauch, Wolfgang Hoffmann, Henry Völzke, William H Krüger, Andreas Hochhaus, Francesca Palandri, Tina M Schnoeder, Christian Homann, Florian H. Heidel

Blood (2024) 144 (Supplement 1): 1090.

https://doi.org/10.1182/blood-2024-205036

Published: 2024

Journal Articles

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

Luca Lanino, Anthony M. Hunter, Nico Gagelmann, Marie Robin, Claudia Sala, Daniele Dall'Olio, Carmelo Gurnari, Lorenzo Dall'Olio, Yu-Hung Wang, Lisa Pleyer, Blanca Xicoy, Guillermo Montalban-Bravo, Lee-Yung Shih, Tamanna Haque, Omar Abdel-Wahab, Klaus Geissler, Alex Bataller, Alexandre Bazinet, Manja Meggendorfer, Ilaria Carola Casetti, Elisabetta Sauta, Erica Travaglino, Laura Palomo, Lurdes Zamora, David Quintela, Andres Jerez, Elena Cornejo, Paloma Garcia Martin, Marina Díaz-Beyá, Alejandro Avendaño Pita, Veronica Roldan, Dolly Viviana Fiallo Suarez, Estefania Cerezo Velasco, Marisa Calabuig, Esperanza Such, Guillermo Sanz, Anne Sophie Kubasch, Cristina Castilla-Llorente, Claude-Éric Bulabois, Laetitia Souchet, Hussein Awada, Massimo Bernardi, Patrizia Chiusolo, Antonio Curti, Luisa Giaccone, Francesco Onida, Lorenza Maria Borin, Francesco Passamonti, Elisa Diral, Vladan Vucinic, Gregorio Maria Bergonzi, Maria Teresa Voso, Hsin-An Hou, Wen-Chien Chou, Chi-Yuan Yao, Chien-Chin Lin, Hwei-Fang Tien, Alessia Campagna, Marta Ubezio, Antonio Russo, Gabriele Todisco, Giulia Maggioni, Cristina Astrid Tentori, Alessandro Buizza, Gianluca Asti, Matteo Zampini, Elena Riva, Mattia Delleani, Angela Consagra, Francesca Ficara, Armando Santoro, Luciana Carota, Tiziana Sanavia, Cesare Rollo, Ahmad Kiwan, Jennifer VanOudenhove, Piero Fariselli, Najla H. Al Ali, David Sallman, Wolfgang Kern, Guillermo Garcia-Manero, Swapna Thota, Elizabeth A. Griffiths, Matilde Yung Follo, Carlo Finelli, Uwe Platzbecker, Francesc Sole, Maria Diez-Campelo, Jaroslaw Maciejewski, Rafael Bejar, Felicitas R. Thol, Nicolaus Kröger, Pierre Fenaux, Raphael Itzykson, Timothy Aaron Graubert, Michaela Fontenay, Amer M. Zeidan, Rami S. Komrokji, Valeria Santini, Torsten Haferlach, Ulrich Germing, Saverio D'Amico, Gastone Castellani, Mrinal M. Patnaik, Eric Solary, Eric Padron, Matteo Giovanni Della Porta

Blood (2024) 144 (Supplement 1): 1003.

https://doi.org/10.1182/blood-2024-200104

Published: 2024

Journal Articles

CAR-T Cell Therapy for Acquired Hemophilia A

Blood (2024) 144 (Supplement 1): 5503.

https://doi.org/10.1182/blood-2024-202970

Published: 2024

Journal Articles

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln-049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease

Blood (2024) 144 (Supplement 1): 2883.1.

https://doi.org/10.1182/blood-2024-201478

Published: 2024

Journal Articles

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Jan-Niklas Eckardt, Marius Bill, Konstanze Döhner, Christian Rausch, Klaus H Metzeler, Karsten Spiekermann, Sebastian Stasik, Tim Sauer, Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H. H. Brummendorf, Utz Krug, Bernhard Wörmann, Hermann Einsele, Wolfgang Hiddemann, Dennis Görlich, Maria Cristina Sauerland, Björn Steffen, Andreas Neubauer, Andreas Burchert, Kerstin Schaefer-Eckart, Wolfgang E. Berdel, Christoph Schliemann, Stefan W. Krause, Mathias Hänel, Maher Hanoun, Martin Kaufmann, Lars Fransecky, Jan Braess, Johannes Schetelig, Jan Moritz Middeke, Lars Bullinger, Michael Heuser, Felicitas R Thol, Hubert Serve, Claudia D Baldus, Uwe Platzbecker, Carsten Mueller-Tidow, Barbora Weinbergerova, Jiri Mayer, Pierre-Yves Dumas, Sarah Bertoli, Eric Delabesse, Christian Récher, Arnaud Pigneux, Tobias Herold, Arnold Ganser, Hartmut Döhner, Martin Bornhäuser, Christian Thiede, Christoph Röllig

Blood (2024) 144 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2024-201945

Published: 2024

Journal Articles

Prognostic Role of NGS-Based MRD Assessment in FLT3 -TKD Mutated Patients with Acute Myeloid Leukemia

Isabell Arnhardt, Christian M. Vonk, Xavier Cheng-Hong Tsai, Felicitas R. Thol, Wen-Chien Chou, Hsin-An Hou, Razif Gabdoulline, Florian H. Heidel, Hwei-Fang Tien, Michael Heuser, Peter J. M. Valk

Blood (2024) 144 (Supplement 1): 2951.

https://doi.org/10.1182/blood-2024-207981

Published: 2024

Journal Articles

Intra-Tumor Heterogeneity in Core-Binding Factor Acute Myeloid Leukemia

Raphael Hablesreiter, Paulina Strzelecka, Natalia Estrada, Klara Kopp, Anna Dolnik, Marlon Tilgner, Coral Fustero, Felicitas R Thol, Florian H. Heidel, Michael Heuser, Lars Bullinger, Friederike Christen, Frederik Damm

Blood (2024) 144 (Supplement 1): 2956.

https://doi.org/10.1182/blood-2024-202342

Published: 2024

Journal Articles

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1 -Mutated Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 2010–2013.

https://doi.org/10.1182/blood-2022-166084

Published: 2022

Journal Articles

Fla-IDA Chemotherapy with or without Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 3315–3316.

https://doi.org/10.1182/blood-2022-163430

Published: 2022

Journal Articles

Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features

Blood (2022) 140 (Supplement 1): 9824–9827.

https://doi.org/10.1182/blood-2022-164816

Published: 2022

Journal Articles

TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis

Nico Gagelmann, Anita Badbaran, Rachel Beth Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Arnold Ganser, Christina Rautenberg, Bruno Cassinat, Felicitas R Thol, Christine Wolschke, Marie Robin, Michael Heuser, Marie Thérèse Rubio, Jaroslaw P. Maciejewski, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kroeger

Blood (2022) 140 (Supplement 1): 828–829.

https://doi.org/10.1182/blood-2022-158900

Published: 2022

Journal Articles

Rapid and Reproducible Karyotyping with Nanopore Sequencing in AML Patients

Blood (2022) 140 (Supplement 1): 6070–6072.

https://doi.org/10.1182/blood-2022-163035

Published: 2022

Journal Articles

Prognostic Impact of Clonal Hierarchy of Myelodysplasia-Related Gene Mutations in AML Patients

Rabea Mecklenbrauck, Nora Borchert, Carolin Funke, Maximilian Brandes, Louisa-Kristin Dallmann, Piroska Klement, Walter Fiedler, Jürgen Krauter, Arne Trummer, Bernd Hertenstein, Andreas Voss, Michael Lübbert, Verena I. Gaidzik, Konstanze Döhner, Hartmut Döhner, Arnold Ganser, Felicitas R. Thol, Michael Heuser

Blood (2022) 140 (Supplement 1): 6254–6255.

https://doi.org/10.1182/blood-2022-162725

Published: 2022

Journal Articles

Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Maria Sirenko, Elsa Bernard, David B. Beck, Maria Creignou, Dylan Domenico, Andrea Farina, Juan E Arango, Olivier Kosmider, Robert P. Hasserjian, Martin Jadersten, Ulrich Germing, Guillermo Sanz, Arjan A. van de Loosdrecht, Matilde Y Follo, Felicitas R. Thol, Lurdes Zamora, Ronald Feitosa Pinheiro, Andrea Pellagatti, Harold K. Elias, Detlef Haase, Christina Ganster, Lionel Ades, Magnus Tobiasson, Laura Palomo, Matteo G. Della Porta, Kety Huberman, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia M. Klimek, Fabio Pires de Souza Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Seishi Ogawa, Michaela Fontenay, Joop H. Jansen, Jose Cervera, Benjamin L. Ebert, Rafael Bejar, Peter L Greenberg, Norbert Gattermann, Luca Malcovati, Mario Cazzola, Eva Hellström-Lindberg, Elli Papaemmanuil

Blood (2022) 140 (Supplement 1): 9785–9788.

https://doi.org/10.1182/blood-2022-162397

Published: 2022

Journal Articles

Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All- Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)

Inga Hund, Maria Hess, Julia Stomper, Gabriele Greve, Jan Mitschke, Christoph Niemöller, Tobias Ma, David Uhl, Felicitas R. Thol, Michael Heuser, Gesine Bug, Martina Crysandt, Lutz Peter Mueller, Andreas Neubauer, Justus Duyster, Hartmut Dohner, Melanie Boerries, Heiko Becker, Michael Luebbert

Blood (2022) 140 (Supplement 1): 3383–3384.

https://doi.org/10.1182/blood-2022-163220

Published: 2022

Journal Articles

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

Hartmut Döhner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas R. Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueño, Esther T. Chan, Anjan Thakurta, C.L. Beach, Daniel Lopes de Menezes

Blood (2022) 140 (15): 1674–1685.

https://doi.org/10.1182/blood.2022016293

Published: 2022

Includes: Supplemental data

Journal Articles

Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications

Blood (2021) 138 (Supplement 1): 692.

https://doi.org/10.1182/blood-2021-147256

Published: 2021

Journal Articles

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

Hartmut Döhner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas R Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueño, Esther Chan, Anjan Thakurta, C.L. Beach, Daniel Lopes de Menezes

Blood (2021) 138 (Supplement 1): 804.

https://doi.org/10.1182/blood-2021-147465

Published: 2021

NARROW

Prognostic Impact of Subclinical FLT3 -ITD Microclones in Patients with Acute Myeloid Leukemia

The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3 -ITD Mutations

Reliable Assessment of Iron Deficiency in Patients with Myeloproliferative Neoplasms through Fluorescence Spectroscopy-Based Measurement of Zinc Protoporphyrin (ZPP)

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

CAR-T Cell Therapy for Acquired Hemophilia A

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln-049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease

The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Prognostic Role of NGS-Based MRD Assessment in FLT3 -TKD Mutated Patients with Acute Myeloid Leukemia

Intra-Tumor Heterogeneity in Core-Binding Factor Acute Myeloid Leukemia

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1 -Mutated Acute Myeloid Leukemia

Fla-IDA Chemotherapy with or without Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features

TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis

Rapid and Reproducible Karyotyping with Nanopore Sequencing in AML Patients

Prognostic Impact of Clonal Hierarchy of Myelodysplasia-Related Gene Mutations in AML Patients

Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All- Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only